BridgeBio Pharma to Present Preliminary Findings on its Novel Bioassay Measuring Glycosylated Alpha-dystroglycan (⍺DG) in Patients with Limb-girdle Muscular Dystrophy Type 2I (LGMD2I)

March 17, 2023

https://www.globenewswire.com/news-release/2023/03/17/2629410/0/en/BridgeBio-Pharma-to-Present-Preliminary-Findings-on-its-Novel-Bioassay-Measuring-Glycosylated-Alpha-dystroglycan-DG-in-Patients-with-Limb-girdle-Muscular-Dystrophy-Type-2I-LGMD2I.html

– BridgeBio will also share 15-month Phase 2 data and review the Phase 3 clinical trial design of BBP-418, a potential therapeutic for patients with LGMD2I, with initiation of its Phase 3 study expected in mid-2023

Read more at globenewswire.com

Related news for (BBIO)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.